INCLUSION CRITERIA:  Aged >=18 years. Documented SCN due to G6PC3 deficiency defined by genetic testing. History of ANC consistently <1000 cells/microL when not treated with G-CSF. Current ANC<1000 cells/microL when not treated with G-CSF.  Participants must agree not to become pregnant for the duration of the study. Study participants must use 2 methods of birth control when engaging in sexual activities that can result in pregnancy, beginning 30 days before the first dose of empagliflozin through one month after treatment ends. One method must be a male or female condom. The other method may be any of the following:  Hormonal contraception. Diaphragm or cervical cap with a spermicide. Intrauterine device. Able to provide informed consent.  EXCLUSION CRITERIA:  Individuals meeting any of the following criteria will be excluded from study participation:  Renal failure or eGFR<45 mL/min/1.73 m^2. Type 1 diabetes mellitus. Fasting hypoglycemia (<60 mg/dL). Known hypersensitivity or allergy to any component of empagliflozin. Pregnant. Breastfeeding. Any condition that, in the opinion of the investigator, contraindicates participation in this study.